Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down to $2.57

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) gapped down before the market opened on Wednesday . The stock had previously closed at $2.57, but opened at $2.50. Taysha Gene Therapies shares last traded at $2.91, with a volume of 578,384 shares.

Wall Street Analyst Weigh In

TSHA has been the subject of several research analyst reports. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Wednesday. Canaccord Genuity Group reiterated a "buy" rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday, March 21st. Piper Sandler assumed coverage on shares of Taysha Gene Therapies in a report on Tuesday, April 9th. They set an "overweight" rating and a $9.00 target price for the company. Chardan Capital upped their price target on shares of Taysha Gene Therapies from $5.00 to $7.00 and gave the company a "buy" rating in a report on Thursday, March 21st. Finally, JMP Securities reissued a "market outperform" rating and set a $5.00 price objective on shares of Taysha Gene Therapies in a research note on Wednesday, March 20th. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Taysha Gene Therapies presently has a consensus rating of "Buy" and an average price target of $7.00.

Taysha Gene Therapies Stock Performance

The stock's fifty day moving average is $2.61 and its two-hundred day moving average is $2.11. The firm has a market capitalization of $581.63 million, a price-to-earnings ratio of -4.48 and a beta of 0.37. The company has a debt-to-equity ratio of 0.54, a quick ratio of 4.08 and a current ratio of 4.08.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.10) earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.01. The firm had revenue of $3.41 million for the quarter, compared to analyst estimates of $3.70 million. During the same period in the previous year, the business posted ($0.28) earnings per share. Analysts forecast that Taysha Gene Therapies, Inc. will post -0.39 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Howard Capital Management Inc. acquired a new position in shares of Taysha Gene Therapies in the 4th quarter valued at about $25,000. Victory Capital Management Inc. acquired a new position in shares of Taysha Gene Therapies in the 4th quarter valued at about $28,000. Dynamic Technology Lab Private Ltd acquired a new position in Taysha Gene Therapies during the 4th quarter valued at about $31,000. Lee Financial Co acquired a new position in Taysha Gene Therapies during the 3rd quarter valued at about $63,000. Finally, China Universal Asset Management Co. Ltd. acquired a new position in Taysha Gene Therapies during the 4th quarter valued at about $38,000. 77.70% of the stock is owned by institutional investors and hedge funds.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.